Article

Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacy

2023-08-25

Abstract excerpt

There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of afatinib, a pan-HER tyrosine kinase inhibitor, in a window-of-opportunity trial (NCT01415674). Multi-omics analyses were carried out on pre-treatment biopsy and surgical specimen for biological assessment of afatinib...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 51f9bc2f-0494-5a85-ab94-ed3a4b53368e
DOI: 10.21203/rs.3.rs-3163648/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacyDOI 10.21203/rs.3.rs-3163648/v1Read

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.Semantic proximity Read

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.Semantic proximity Read

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.Semantic proximity Read

A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.Semantic proximity Read

Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For <i>In Vitro</i> Sensitivity to GefitinibSemantic proximity Read

Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.Semantic proximity Read

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.Semantic proximity Read

Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.Semantic proximity Read

Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinomaSemantic proximity Read

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axisSemantic proximity Read

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.Semantic proximity Read

Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.Semantic proximity Read